Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $105.8 million.

  • Akebia Therapeutics' Non-Current Assets fell 112.69% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $430.0 million, marking a year-over-year decrease of 470.12%. This contributed to the annual value of $106.8 million for FY2024, which is 1352.85% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Non-Current Assets of $105.8 million as of Q3 2025, which was down 112.69% from $110.9 million recorded in Q2 2025.
  • Akebia Therapeutics' Non-Current Assets' 5-year high stood at $280.8 million during Q2 2021, with a 5-year trough of $105.8 million in Q3 2025.
  • For the 5-year period, Akebia Therapeutics' Non-Current Assets averaged around $168.8 million, with its median value being $135.3 million (2023).
  • Per our database at Business Quant, Akebia Therapeutics' Non-Current Assets crashed by 4100.5% in 2021 and then skyrocketed by 262.63% in 2025.
  • Akebia Therapeutics' Non-Current Assets (Quarter) stood at $258.2 million in 2021, then tumbled by 33.82% to $170.9 million in 2022, then fell by 27.69% to $123.6 million in 2023, then decreased by 13.53% to $106.8 million in 2024, then dropped by 0.96% to $105.8 million in 2025.
  • Its Non-Current Assets was $105.8 million in Q3 2025, compared to $110.9 million in Q2 2025 and $106.4 million in Q1 2025.